[Synergistic interaction between Ys-96, a bisbenzylisoquinoline compound derived from Stephania tetrandra, and adriamycin or vincristine against human cancer cell lines in vitro].
To study in vitro the anticancer interaction between Ys-96, a bisbenzylisoquinoline compound derived from Stephania tetrandra, and adriamycin or vincristine against human cancer cell lines. Using human breast cancer cell MCF-7 and its adriamycin-resistant cell line MCF-7/Adr, and human nasopharyngeal cancer cell KB and its vincristine-resistant cell line KBv200 in an in vitro system, anticancer interaction between Ys-96 and adriamycin or vincristine was evaluated with a method reported by Berenbaum. The SFIC values (sum of fractional inhibitory concentration) of the combinations with 3 different ratios between Ys-96 and adriamycin or vincristine were markedly less than 1.0, and the shapes of all the isobologram curves were concave. The synergistic interaction between Ys-96 and adriamycin or vincristine against the above human cancer cell lines was positively observed in vitro.